Loading chat...
IN HB1449
Bill
Status
4/16/2015
Primary Sponsor
Steven Davisson
Click for details
AI Summary
HB 1449 Summary
-
Medicaid reimbursement for Subutex, Suboxone, and generic equivalents for pain management requires prescribers to have federal SAMHSA waiver and DEA authorization for office-based opioid addiction treatment, effective July 1, 2015.
-
Prior authorization may be required for these drugs when prescribed for substance abuse treatment beyond 6 months or as determined by the board.
-
Division of mental health and addiction may approve up to 5 new opioid treatment programs before June 30, 2018, only if operated by hospitals or certified community mental health centers and if geographic need is demonstrated.
-
Division must report to general assembly by June 30, 2018, on access impact, individuals served, treatment outcomes, and recommendations for any new programs approved.
-
Opioid treatment providers must periodically and randomly test patients for methadone, cocaine, opiates, amphetamines, barbiturates, THC, benzodiazepines, and other suspected drugs; division must adopt rules for take-home medication, patient tapering, relapse, and overdose prevention standards.
Legislative Description
Opioid treatment. Limits Medicaid reimbursement for Subutex and Suboxone or an similar trade name or generic of the drug when the drug was prescribed for the treatment of pain management to only if the drug was prescribed by a physician who meets certain requirements. Allows for the office of Medicaid policy and planning to require prior authorization for these drugs when being prescribed for substance abuse treatment as determined by the board or when being prescribed for more than six months. Authorizes the division of mental health and addiction (division) to approve before June 30, 2018, not more than five
Last Action
Senate Advisors appointed: Miller Patricia, Breaux and Grooms
4/20/2015